贫血，微蛋白尿和的肾小球滤过滤评估与心血管疾病及随后的死亡之间的关系还没有充分弄清楚。
Background The relationships of anemia, microalbuminuria, and estimated glomerular filtration rate (eGFR) with cardiovascular disease (CVD) and subsequent death are not fully understood.
初级评估疗效指标是肾小球过滤率的变化，观察在18个月和36个月（3年）的肾小球滤过率（GFR）变化。
The primary outcome measure was progression of nephropathy, which was assessed by change in glomerular filtration rate (GFR) at 18 and 36 months.
初级评估疗效指标是肾小球过滤率的变化，观察在18个月和36个月（3年）的肾小球滤过率（GFR）变化。
The primary outcome measure was progression of nephropathy, which was assessed by change in glomerular filtration rate (GFR) at 18 and 36 months.
应用推荐